LEAF’s monthly roundup for May is out!
Summer is coming, and, albeit on a slightly longer timeframe, so is a world free of aging! So, grab an iced drink, sit comfortably on your beach chair, and let’s have a look together at some of the latest rejuvenation news.
The first LEAF conference in NYC is coming!
With the ability to be coaxed into different kinds of mature cell types, induced pluripotent stem cells (iPSCs) hold all kinds of potential in the world of regenerative medicine. One of the many possibilities could be repairing damaged hearts, something that will soon be put to the test for the first time ever in newly approved clinical trials in Japan.
Since emerging from the laboratory of researcher Shinya Yamanaka in Japan in 2006, the potential of iPSCs has been explored in all kinds of promising research efforts. We have seen them implanted into rabbits to restore their vision, become brain tumor predators, and turned into precursor cells for human organs.
IPSCs are created by first harvesting cells from body tissues and then infecting them with a virus, in turn introducing them to carefully selected genes that return them to their immature state. From there they can develop into any cell in the body, a capability so powerful it earned Yamanaka a Nobel Prize in 2012.
Researchers at Queen Mary University of London have developed a new way to grow mineralised materials which could regenerate hard tissues such as dental enamel and bone.
Enamel, located on the outer part of our teeth, is the hardest tissue in the body and enables our teeth to function for a large part of our lifetime despite biting forces, exposure to acidic foods and drinks and extreme temperatures. This remarkable performance results from its highly organised structure.
However, unlike other tissues of the body, enamel cannot regenerate once it is lost, which can lead to pain and tooth loss. These problems affect more than 50 per cent of the world’s population and so finding ways to recreate enamel has long been a major need in dentistry.
Continue reading “Scientists develop material that could regenerate dental enamel” »
Forget zombies or killer robots – the most likely doomsday scenario in the near future is the threat of superbugs. Bacteria are evolving resistance to our best antibiotics at an alarming rate, so developing new ones is a crucial area of study. Now, inspired by a natural molecule produced by marine microorganisms, researchers at North Carolina State University have synthesized a new compound that shows promising antibacterial properties against resistant bugs.
Decades of overuse and overprescription of antibiotics has led to more and more bacteria becoming resistant to them, and the situation is so dire that a recent report warned that they could be killing up to 10 million people a year by 2050. Worse still, the bugs seem to be on schedule, with the ECDC reporting that our last line of defense has already begun to fail in large numbers.
https://www.engadget.com/…/3D-printed-brain-medical-imagin…/
There are almost limitless possibilities when it comes to 3D printing. Design your own color-changing jewelry? Fine. Fabricate your own drugs? No problem. Print an entire house in under 24 hours? Sure! Now, researchers have come up with a fast and easy way to print palm-sized models of individual human brains, presumably in a bid to advance scientific endeavours, but also because, well, that’s pretty neat.
In theory, creating a 3D printout of a human brain has been done before, using data from MRI and CT scans. But as MIT graduate Steven Keating found when he wanted to examine his own brain following his surgery to remove a baseball-sized tumour, it’s a slow, cumbersome process that doesn’t reveal any important areas of interest.
Continue reading “You’ll soon be able to get a 3D printed model of your brain” »
I will be 85 somewhere in the mid 2050s. It seems like a mirage, an impossible thing, but the future eventually arrives regardless of whatever you or I might think about it. We all have a vision of what it is to be 85 today, informed by our interactions with elder family members, if nothing else. People at that age are greatly impacted by aging. They falter, their minds are often slowed. They are physically weak, in need of aid. Perhaps that is why we find it hard to put ourselves into that position; it isn’t a pleasant topic to think about. Four decades out into the future may as well be a science fiction novel, a far away land, a tale told to children, for all the influence it has on our present considerations. There is no weight to it.
When I am 85, there will have been next to no senescent cells in my body for going on thirty years. I bear only a small fraction of the inflammatory burden of older people of past generations. I paid for the products of companies descended from Oisin Biotechnologies and Unity Biotechnology, every few years wiping away the accumulation of senescent cells, each new approach more effective than the last. Eventually, I took one of the permanent gene therapy options, made possible by biochemical discrimination between short-term beneficial senescence and long-term harmful senescence, and then there was little need for ongoing treatments. Artificial DNA machinery floats in every cell, a backup for the normal mechanisms of apoptosis, triggered by lingering senescence.
When I am 85, the senolytic DNA machinery will be far from the only addition to my cells. I underwent a half dozen gene therapies over the years. I picked the most useful of the many more that were available, starting once the price fell into the affordable-but-painful range, after the initial frenzy of high-cost treatments subsided into business as usual. My cholesterol transport system is enhanced to attack atherosclerotic lesions, my muscle maintenance and neurogenesis operate at levels far above what was once a normal range for my age, and my mitochondria are both enhanced in operation and well-protected against damage by additional copies of mitochondrial genes backed up elsewhere in the cell. Some of these additions were rendered moot by later advances in medicine, but they get the job done.
Earlier this month, there was a human clinical trial of the supplement MitoQ, which showed some interesting results. We thought that we would take a look at the data, and discuss the findings.
Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60–79 years) with impaired endothelial function (brachial artery flow–mediated dilation 6%) underwent 6 weeks of oral supplementation with MitoQ (20 mg/d) or placebo in a randomized, placebo-controlled, double-blind, crossover design study.
New video from Undoing Aging 2018: Mike West, Founder, and CEO of AgeX, presenting their work on induced tissue regeneration: Leveraging the unique regenerative potential of pluripotent stem-cell-derived therapeutics.
Accelerating rejuvenation therapies to repair the damage of aging. Berlin, March, 15 — 17.
